It is with great pleasure that Synergy Pharmaceuticals was able to present the latest research journal the “Isolation and elimination of Latent and Productive Herpes Simplex Virus from the Sacral and Trigeminal Ganglions” at the recent Third Global Experts Meeting on Infectious Diseases January 2020. Building on this, Synergy are also glad to announce their contribution to the world conference Viruses 2020 – Novel Concepts in Virology held in Barcelona, Spain, 5-7 February 2020.
Synergy Pharmaceuticals are honored to have been selected to present at the International Conference on Immunity and Diagnosis of Viral Infections in Tokyo Japan 2020.
Latest Press Releases
Novel approach from Synergy Pharmaceuticals may hold cure to herpes virus
Sydney, Aus, Feb 11, 2020 – (Bloomberg)
There is an immediate need for alternative treatments to combat the spread of Herpes type 1 & 2 strains.
The United States alone reports over 750,000 new cases of herpes infections every year. Alarming figures especially when coupled with the increased risk for pregnant women, newborn babies and with the incidence of herpes encephalitis on the rise. Existing options include antivirals that have been approved for clinical administration and a limited number of nucleoside analogues.
A recent study by Synergy Pharmaceuticals in Australia may set a new stream of thought on the topic by bringing back traditional medicine as an opportunity to make a difference. Their study served to investigate a relatively novel approach to breaking down the herpes viral envelope by employing specific T Cells generated through a particular Amino Acid formula.
The treatment consisted of five immunotherapeutic core compounds (5CC) comprising Rhodiola, Tribulus, Astragalus, Lysine and a proprietary Amino Acid Formula. These 5CC are effective inhibitors of herpes viral DNA synthesis and interferon (IFN)-induced cellular antiviral response and were found to neutralize antiviral reproduction by blocking cell-to-cell infection.
The aim of this study was to explore alternative substitutes to treat herpes simplex virus infection and prevent viral reproduction where conventional medications had previously failed. Testing was performed using 5CC with immunotherapeutic features to be able to neutralize herpes viral activity inside the human body. For the first time, this study highlighted the combinations capacity to act by preventing cell-to-cell infection to suppress the activity of the virus.
The study also focused on the immune-inhibiting properties of the 5CC which indicated cell membrane breakdown and eradication. A randomized, investigator-blinded method was performed on patients with a moderate to high positive concentration of herpes serum antibodies. A longitudinal approach was adopted over 6 months, where participants’ infection rates were measured at various points during the treatment. Antiviral activity of the 5CC against HSV-1 and HSV-2 was tested on RC-37 cells in vitro using a plaque reduction assay.
The study was able to validate that for some participants there was a noted progression from a positive antibody serology to a negative one. This was the first time evidence has documented a cure for the herpes simplex virus.
This research shows considerable scope, particularly in the natural approach to viral infection treatment options, while it is the first study that has documented herpes serum antibody results that confirmed a positive to negative transition for participants. The results validated the earlier aims that 5CC provides far greater elimination in viral cell breakdown than any other conventional antiviral medication or vaccine thus far. Indicators of the 5CC found that the combination exhibited high levels of virucidal activity against HSV-1 and HSV-2 in viral suspension. These results suggest that the 5CC are strong alternative candidates for treating herpes simplex.
Follow up investigations have demonstrated further promising results, still utilising the same 5CC from the study. In light of this research and the current demands for a more natural approach, Synergy has seen expansion across the Australian, American and Asian markets. Further avenues into Europe appear to be stagnant however due to limitations on the accessibility of imported natural medicine, a situation which may serve to highlight the drastic shortcomings in the over-regulation of health and supplements.
While this appears to be the first and only successful cure for the herpes virus the researchers went on to reflect; there is however, no immunity for sufferers once clear of the herpes virus, potentially leaving the door open to reinfection later if the individual is not careful. This study though may well pave the way for a departure from the standard antiviral pharmaceutical mentality, which has dominated medical profession culture on the treatment options for viral disease for so many years.
1. CDC. (January 31, 2017). Genital Herpes – CDC Fact Sheet (Detailed).
2. American Sexual Health Association. (April 18, 2019). Herpes treatment.
3. May, Brandon. (July 10, 2018). Abandoned Genital Herpes Vaccine GEN-003. Found to Reduce Lesions, Decrease Viral Shedding at Varying Doses.
4. Taylor, Marisa. (April 12, 2018). FDA Launches Criminal Investigation Into Unauthorized Herpes Vaccine Research.
5. Raymond, Nate. (December 7, 2018). Genocea Biosciences ducks investor lawsuit over herpes vaccine.
6. Sciforum Journals. (December 20, 2019). Isolation and elimination of Latent and Productive Herpes Simplex Virus from the Sacral and Trigeminal Ganglions.
7. Berman, Robby. (November 23, 2019). How dormant herpes springs back to life.
Synergy Presentation International Conference on Immunity and Diagnosis of Viral Infections Tokyo Japan 2020
by Bernard Middleton and Susan Michelle Cosgrove
Source: International Journal of Medical and Health Sciences Vol:14, No:02, 2020
Dormant viruses activate during spaceflight
Frontiers “The stress of spaceflight gives viruses a holiday from immune surveillance, putting future deep-space missions in jeopardy”
Could there finally be a cure on the horizon for herpes sufferers
“Breakthrough Discovery in the Battle Against the Herpes Simplex Virus”
Source: London Post
Researchers have identified a defect in the immune system which causes some people to develop life threatening inflamation of the brain.
Aarhus University. “Cause of viral infection of the brain mapped out.”
In general the Herpes virus is considered to be species specific, however new Findings have shown that the virus can jump from the host animal to other species causing fatalities.
Forschungsverbund Berlin e.V. (FVB).
“Herpes viruses with an unusual broad host range.”
Explanation of the neurological damage to the brain caused by the Herpes virus.
What Does Herpes Do To Your Brain?
Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle.
Targeting different steps of the herpes virus life cycle, including entry and cell-to-cell infection,
Source: Science Direct
Autism risk linked to herpes infection during pregnancy.
Women actively infected with genital herpes during early pregnancy had twice the odds of giving birth to a child later diagnosed with autism spectrum disorder, according to a new study.
Source: Columbia University’s Mailman School of Public Health
Herpes virus linked to most common type of childhood cancer.
Newborns with congenital cytomegalovirus — a common virus in the herpes family — may have an increased risk of developing acute lymphocytic leukemia, according to new research. The study suggests the risk is even greater in Hispanic children.
Source: American Society of Hematology
Woman says her twins were stillborn after she contracted herpes from Usher
By Kelly Mclaughlin & Chris Spargo for the Daily Mail
Could Alzheimer’s Be a Reaction to Infection?
“A relatively new and still controversial theory suggests the disease could be triggered by pathogens”
By Kenneth Shinozuka, Dhruva Gupta
Source: Scientific American
Natural Herpes Cure Poised to Overcome Limitations of Antivirals
Source: Yale University